Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C

Journal of Infectious Diseases

Volumn 195, Issue 7, 2007, Pages 973-979

  Barreiro, Pablo ^a   Rodríguez Novoa, Sonia ^a   Labarga, Pablo ^a   Ruiz, Andrés ^a   Jiménez Nácheir, Inmaculada ^a   Martín Carbonero, Luz ^a   Gonzalez Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; ELASTOMETRY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER CLEARANCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; DRUG MONITORING; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; NEVIRAPINE; OLIGOPEPTIDES; OXAZINES; PYRIDINES; PYRIMIDINONES; RITONAVIR; SEVERITY OF ILLNESS INDEX;

EID: 33947430611     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/512086     Document Type: Article

References (26)

1. Sulkowski M, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
2. Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005; 40:588-93.
3. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection: updated recommendations from the HIV-HCV International Panel. AIDS 2004; 18:1-12.
4. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis 2005; 40:174-81 [erratum: Clin Infect Dis 2005; 40:913].
5. Almond L, Boffito M, Hoggard P, et al. The relationship between nevirapine plasma concentrations and abnormal liver function test. AIDS Res Hum Retroviruses 2004; 20:716-22.
6. Nunes D, Fleming C, Offner G, et al. HIV infection does not affect the performance of non-invasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005; 40:538-44.
7. de Ledinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41:175-9.
8. Tribut O, Arvieux C, Michelet C, Chapplain J, Allain H, Bentue-Ferrer D. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography. Ther Drug Monit 2002; 24:554-62.
9. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
10. Khoo S, Lloyd I, Dalton M, et al. Pharmacologic optimization of protease inhibitor and non-nucleoside reverse transcriptase inhibitors (POPIN) - a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr 2006; 41:461-7.
11. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-50.
12. Howden C, Birnie G, Brodie M. Drug metabolism in liver disease. Pharmacol Ther 1989; 40:439-74.
13. George J, Murray M, Byth K. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 1995; 21:120-8.
14. Frye R, Zgheib N, Matzke G, et al. Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther 2006; 80:235-45.
15. Dominguez S, Peytavin G, Guiget M, et al. The HEPADOSE study: evaluation of protease inhibitors and non nucleoside analogue plasma concentrations in HIV/HCV and HIV-infected patients [abstract WePp0305]. In: Program and abstracts of the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment (Rio de Janeiro). San Francisco: International AIDS Society, 2005:246.
16. Dominguez S, Benhamou Y, Katlama C, Peytavin G. Nevirapine plasma concentrations in HIV/HCV and HIV infected patients, a case control study: NEVADOSE [abstract 21]. In: Program and abstracts of the 2nd International Workshop on Clinical Pharmacology of HIV Therapy (Amsterdam). Utrecht: Virology Education Publications, 2006:74.
17. Ward B, Gorski J, Jones D, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306:287-300.
18. Erickson D, Mather G, Trager W, Levy R, Keirns J. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27:1488-95.
19. George J, Murray M, Byth K, Farrell G. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 1995; 21:120-8.
20. Guengerich F, Turvey C. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991; 256:1189-94.
21. Gonzalez de Requena D, Jiménez-Nácher I, Soriano V. Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations. AIDS Res Hum Retroviruses 2005; 21:555-9.
22. Dailly E, Billaud E, Reliquet V, et al. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol 2004; 60:343-8.
23. Peng J, Pulido F, Causemaker S, et al. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment. J Clin Pharmacol 2006; 46:265-74.
24. Herold C, Ganslmayer M, Ocker M, et al. Inducibility of microsomal liver function may differentiate cirrhotic patients with maintained compared with severely compromised liver reserve. J Gastroenterol Hepatol 2003; 18:445-9.
25. Regazzi M, Maserati R, Villani P, et al. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in HIV-positive and HIV-hepatitis C virus-coinfected subjects. Antimicrob Agents Chemother 2005; 49:643-9.
26. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (Fibroscan): a prospective study. Gut 2006; 55:403-8.